Cargando…

Targeting continuity of care and polypharmacy to reduce drug–drug interaction

Drug–drug interaction (DDI) is common among the elderly, and it can have detrimental effects on patients. However, how DDI can be targeted has been under-researched. This study investigates whether DDI can be reduced by targeting continuity of care (COC) through reducing polypharmacy. Population cla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weng, Yi-An, Deng, Chung-Yeh, Pu, Christy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718252/ https://www.ncbi.nlm.nih.gov/pubmed/33277524 http://dx.doi.org/10.1038/s41598-020-78236-y

Ejemplares similares

Polypharmacy and potential drug–drug interactions among Greenland’s care home residents
por: Albertsen, Nadja, et al.
Publicado: (2022)

Drug-drug interactions in polypharmacy patients: The impact of renal impairment
por: Papotti, Bianca, et al.
Publicado: (2021)

Polypharmacy and potential drug–drug interactions in emergency department patients in the Caribbean
por: Dookeeram, Darren, et al.
Publicado: (2017)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients
por: Kilit, Türkan Paşalı, et al.
Publicado: (2022)

Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review
por: Rodrigues, Maria Cristina Soares, et al.
Publicado: (2016)

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy
por: Salamone, Sandro, et al.
Publicado: (2022)

Prevalence of Polypharmacy and Drug Interaction Among Hospitalized Patients: Opportunities and Responsabilities in Pharmaceutical Care
por: Trumic, Edisa, et al.
Publicado: (2012)

POLYPHARMACY VERSUS DRUG COMBINATIONS
por: Agarwal, A.K.
Publicado: (1991)

Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy
por: Bachmann, Paula, et al.
Publicado: (2022)

Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms
por: Krečak, Ivan, et al.
Publicado: (2023)

The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010
por: Guthrie, Bruce, et al.
Publicado: (2015)

Potential for Drug Interactions and Polypharmacy From Treatment of COVID-19 in Long-Term Care
por: Blaszczyk, Amie Taggart, et al.
Publicado: (2022)

The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis
por: Frahm, Niklas, et al.
Publicado: (2020)

Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients
por: Chen, Zhaoyan, et al.
Publicado: (2023)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Polypharmacy and potential drug–drug interactions for people with HIV in the UK from the Climate‐HIV database
por: Okoli, C, et al.
Publicado: (2020)

Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics
por: Georgiev, Kaloyan D., et al.
Publicado: (2022)

The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan
por: Nusair, Mohammad B., et al.
Publicado: (2020)

A study of harmful drug–drug interactions due to polypharmacy in hospitalized patients in Goa Medical College
por: Khandeparkar, Akshay, et al.
Publicado: (2017)

Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States
por: Sheikh-Taha, Marwan, et al.
Publicado: (2021)

Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
por: Farooq, Juveriya, et al.
Publicado: (2023)

Using INTERCheck(®) to Evaluate the Incidence of Adverse Events and Drug–Drug Interactions in Out- and Inpatients Exposed to Polypharmacy
por: Martocchia, Antonio, et al.
Publicado: (2020)

Polypharmacy and Potential Drug–Drug Interactions in Home-Dwelling Older People – A Cross-Sectional Study
por: Hermann, Monica, et al.
Publicado: (2021)

Adverse drug reactions and polypharmacy in cardiac patients
por: Mugoša, Snežana, et al.
Publicado: (2012)

Polypharmacy - is there a cure for drug therapy problems?
por: Orehovački, Helena, et al.
Publicado: (2023)

Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2021)

Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
por: Rutman, Matthew P., et al.
Publicado: (2021)

Adverse drug reactions in the era of multi-morbidity and polypharmacy
por: Birriel, T. Javier, et al.
Publicado: (2015)

Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region
por: Burato, Sofia, et al.
Publicado: (2021)

Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment
por: Ramsdale, Erika, et al.
Publicado: (2022)

Individual Pharmacotherapy Management (IPM)—IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy
por: Wolf, Ursula, et al.
Publicado: (2022)

Top 20 drug − drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients
por: Das, Biswadeep, et al.
Publicado: (2020)

Survey on Polypharmacy and Drug-Drug Interactions Among Elderly People with Cardiovascular Diseases at Yekatit 12 Hospital, Addis Ababa, Ethiopia
por: Assefa, Yelbeneh Abayneh, et al.
Publicado: (2020)

Medication Appropriateness, Polypharmacy, and Drug-Drug Interactions in Ambulatory Elderly Patients with Cardiovascular Diseases at Tikur Anbessa Specialized Hospital, Ethiopia
por: Adem, Limi, et al.
Publicado: (2022)

PB2219: POLYPHARMACY AND DRUG-TO-DRUG INTERACTIONS MAY HAVE A NEGATIVE EFFECT ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

Management of Polypharmacy and Potential Drug–Drug Interactions in Patients with Mycobacterial Infection: A 1-Year Experience of a Multidisciplinary Outpatient Clinic
por: Cattaneo, Dario, et al.
Publicado: (2023)

Opioids, Polypharmacy, and Drug Interactions: A Technological Paradigm Shift Is Needed to Ameliorate the Ongoing Opioid Epidemic
por: Matos, Adriana, et al.
Publicado: (2020)

Targeting neurotransmitter-mediated inflammatory mechanisms of psychiatric drugs to mitigate the double burden of multimorbidity and polypharmacy
por: Matt, Stephanie M.
Publicado: (2021)

SimVec: predicting polypharmacy side effects for new drugs
por: Lukashina, Nina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_emu5vbkqcop51ila6anvae378p